Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736)

NCT03795207 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

96

Enrollment

OTHER

Sponsor class

Conditions

Node; Prostate
Bone Metastases
Prostate Cancer Patients

Interventions

COMBINATION_PRODUCT: SBRT + Durvalumab
RADIATION: SBRT

Sponsor

Institut Cancerologie de l'Ouest

Collaborators

[object Object]